IL-15 by continuous i.v. infusion to adult patients with solid tumors in a Phase I trial induced dramatic NK cell subset expansion

PURPOSE: The first-in-human clinical trial with human bolus i.v. infusion IL-15 (rhIL-15) was limited by treatment-associated toxicity. Here, we report toxicity, immunomodulation, and clinical activity of rhIL-15 administered as a 10-day continuous intravenous infusion (CIV) to patients with cancers...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Cancer Res
Auteurs principaux: Conlon, Kevin C., Potter, E. Lake, Pittaluga, Stefania, Lee, Chyi-Chia Richard, Miljkovic, Milos D., Fleisher, Thomas A., Dubois, Sigrid, Bryant, Bonita R., Petrus, Michael N., Perera, Liyanage P., Hsu, Jennifer, Figg, William D., Peer, Cody J., Shih, Joanna H., Yovandich, Jason L., Creekmore, Stephen P., Roederer, Mario, Waldmann, Thomas A.
Format: Artigo
Langue:Inglês
Publié: 2019
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6697593/
https://ncbi.nlm.nih.gov/pubmed/31142503
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-3468
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires